Back to discover
Drug

Polatuzumab vedotin

Approved medicine
ClassTubulin inhibitorResearchOngoing clinical research

Also known as Polivy.

RxNorm2174090ChEMBLCHEMBL3301582ATCL01FX14UNIIKG6VO684Z6
1
Research papers
43
Active clinical trials
16
Protein targets
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Clinical trial2026-10-16Primary completion · ClinicalTrials.gov

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

Clinical trial2026-10-15Results expected Q2 2030 · ClinicalTrials.gov

Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Clinical trial2026-10-15Primary completion · ClinicalTrials.gov

AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy

Industry2026-10-06Endpoints News

Phase II Study of Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Clinical trial2026-09-25Status changed to Active, not recruiting · ClinicalTrials.gov

A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

Clinical trial2026-09-22Results expected Q1 2028 · ClinicalTrials.gov

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Clinical trial2026-09-18Results expected Q3 2027 · ClinicalTrials.gov

A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Clinical trial2026-09-11Results posted · ClinicalTrials.gov

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Industry2026-08-14Journal of Clinical Oncology

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Clinical trial2026-07-06Trial news · Journal of Clinical Oncology

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Research2021-12-14The New England journal of medicine

Marketing authorisation: Polivy (EMA)

Regulatory2020-01-16EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Polatuzumab vedotin
Aliases & brands
Polivy
RxNorm CUI
2174090
ChEMBL ID
CHEMBL3301582
ATC codes
L01FX14
UNII
KG6VO684Z6
Primary mechanism
Tubulin inhibitor
Regulatory jurisdictions
ema

Pharmacology & targets

16 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Tubulin beta-4B chain
TUBB4B · P68371
INHIBITORTubulin inhibitor
Tubulin beta-1 chain
TUBB1 · Q9H4B7
INHIBITORTubulin inhibitor
Tubulin alpha-3C chain
TUBA3C · P0DPH7
INHIBITORTubulin inhibitor
Tubulin alpha-4A chain
TUBA4A · P68366
INHIBITORTubulin inhibitor
Tubulin beta-3 chain
TUBB3 · Q13509
INHIBITORTubulin inhibitor
Tubulin alpha-1A chain
TUBA1A · Q71U36
INHIBITORTubulin inhibitor
Tubulin beta-4A chain
TUBB4A · P04350
INHIBITORTubulin inhibitor
Tubulin beta-8 chain
TUBB8 · Q3ZCM7
INHIBITORTubulin inhibitor
Tubulin beta chain
TUBB · P07437
INHIBITORTubulin inhibitor
Tubulin alpha-1B chain
TUBA1B · P68363
INHIBITORTubulin inhibitor
Tubulin alpha-1C chain
TUBA1C · Q9BQE3
INHIBITORTubulin inhibitor
Tubulin alpha-3E chain
TUBA3E · Q6PEY2
INHIBITORTubulin inhibitor
Tubulin beta-2A chain
TUBB2A · Q13885
INHIBITORTubulin inhibitor
Tubulin beta-2B chain
TUBB2B · Q9BVA1
INHIBITORTubulin inhibitor
Tubulin beta-6 chain
TUBB6 · Q9BUF5
INHIBITORTubulin inhibitor
B-cell antigen receptor complex-associated protein beta chain
CD79B · P40259
BINDING AGENTB-cell antigen receptor complex-associated protein beta chain binding agent

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2020-01-16
Latest approval
2020-01-16
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2020-01-16Original application approval
Marketing authorisation: Polivy (EMA)
Indication: Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not… Show full indication

Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

66 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
66
registered trials across all phases
LATEST COMPLETION 2026
43
Active studies
26
Recruiting
6
Late-stage (III+)
14
Completed
9
Discontinued
PHASE DISTRIBUTIONn = 66
Phase 19Phase 1 / 218Phase 233Phase 36

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Active, not recruitingPH IIIKey trialHoffmann-La Rochen=1,1302030

A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruitingPH IIIHoffmann-La Rochen=2082027

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

CompletedPH IIIKey trialHoffmann-La Rochen=1,0002026

Open-label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) With Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients With Primary Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

CompletedPH IIIGWT-TUD GmbHn=3062025

A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Alone in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

CompletedPH IIIHoffmann-La Rochen=2702024

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

CompletedPH IIIKey trialHoffmann-La Rochen=1,0002026

Open-label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) With Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients With Primary Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

CompletedPH IIIGWT-TUD GmbHn=3062025

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

CompletedPH I/IIHoffmann-La Rochen=1882025

A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma

CompletedPH IIUniversity of Washingtonn=422025

A Phase Ib Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin (POLA) Plus Rituximab (R), Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

CompletedPH IHoffmann-La Rochen=1112024

A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Alone in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

CompletedPH IIIHoffmann-La Rochen=2702024

Research activity

1 paper

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

The New England journal of medicine · 2022 · 677 cites
Recent papers

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

The New England journal of medicine · 2022 · 677 cites
Journals, researchers & institutions
Top journals
  • The New England journal of medicine1
Leading researchers
  • Abrisqueta P1
  • Bergua-Burgués JM1
  • Burke JM1
  • Chauchet A1
  • Cheung MC1
  • Flowers CR1
  • Friedberg JW1
  • Gau JP1
Leading institutions
free-text, unnormalised
  • Centre Henri-Becquerel and University of Rouen1

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cyclophosphamide

Studied across the same disease area as Polatuzumab vedotin in the shared literature.

1 shared disease1 shared paper
Doxorubicin

Studied across the same disease area as Polatuzumab vedotin in the shared literature.

1 shared disease1 shared paper
Prednisone

Studied across the same disease area as Polatuzumab vedotin in the shared literature.

1 shared disease1 shared paper
Rituximab

Studied across the same disease area as Polatuzumab vedotin in the shared literature.

1 shared disease1 shared paper
Vincristine

Studied across the same disease area as Polatuzumab vedotin in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.